Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

  • 01/04/2023
  • Arno R Bourgonje, Anna Grochot-Przeczek, Antonio Cuadrado, Harry van Goor
By: Arno R Bourgonje, Anna Grochot-Przeczek, Antonio Cuadrado, Harry van Goor. This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)
Go to publication